Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.28 USD
+0.18 (1.49%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $12.28 0.00 (0.00%) 7:18 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.28 USD
+0.18 (1.49%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $12.28 0.00 (0.00%) 7:18 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals (ENTA)
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Enanta Pharmaceuticals (ENTA) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 1.04% and 1.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA)
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Top Performing Stocks of the Best ETF of 1H2018
by Sweta Killa
Inside the top performing stocks of the top ETF of the first half of 2018.
Achieve Life Sciences' Shares Rise on Positive Clinical Data
by Zacks Equity Research
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.
Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.
Top Ranked Momentum Stocks to Buy for June 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 19th:
Play the Best Sector of Summer With These ETFs & Stocks
by Sanghamitra Saha
Health care is apparently one of the best-performing sectors of summer. So, track these ETFs and stocks.
Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon
by Zacks Equity Research
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
Bayer's Generic Competition, Pipeline Setback Issues Remain
by Zacks Equity Research
Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y
by Zacks Equity Research
Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
by Zacks Equity Research
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
by Zacks Equity Research
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
by Zacks Equity Research
Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
by Zacks Equity Research
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
by Zacks Equity Research
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FYC
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down
by Zacks Equity Research
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up
by Zacks Equity Research
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses
by Zacks Equity Research
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.